Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.
Susan C. Modesitt, MD, FACS, FACOG
Advertisement
Articles by Susan C. Modesitt, MD, FACS, FACOG
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
Advertisement
Latest Updated Articles
Inheritance Matters: The Race to Prevent New Ovarian Cancer CasesJanuary 31st 2018
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
5